目的 系統(tǒng)評價茵梔黃口服制劑聯(lián)用雙歧桿菌活菌制劑治療新生兒黃疸的有效性和安全性。方法 檢索2000年1月-2018年12月PubMed、Embase、中國學(xué)術(shù)期刊全文數(shù)據(jù)庫（CNKI）、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫（CBM）、維普中文期刊全文數(shù)據(jù)庫（VIP）和萬方數(shù)據(jù)庫發(fā)表的有關(guān)茵梔黃口服制劑聯(lián)用雙歧桿菌活菌制劑治療新生兒黃疸的隨機(jī)對照試驗(yàn)（RCT），應(yīng)用RevMan 5.3軟件進(jìn)行Meta-分析。結(jié)果 共納入14項(xiàng)RCTs，觀察組和對照組分別為1 042例和972例。Meta-分析結(jié)果顯示：觀察組的痊愈率大于對照組[RR=0.68，95% CI （0.62，0.76），P<0.01]、黃疸消退時間小于對照組[MD=1.97，95% CI （1.77，2.17），P<0.01]、日均膽紅素下降值大于對照組[MD=10.64，95% CI （9.07，12.20），P<0.01]，亞組分析結(jié)果一致。在安全性方面，觀察組不良反應(yīng)（ADR）發(fā)生率小于對照組[RR=1.96，95% CI （1.23，3.13），P<0.01]；亞組分析顯示觀察組ADR發(fā)生率小于空白對照組[RR=2.51，95% CI （1.12，5.66），P=0.03]，但與茵梔黃口服制劑組[RR=1.98，95% CI （0.90，4.33），P>0.05]和雙歧桿菌活菌制劑組[RR=1.45，95% CI （0.62，3.39），P>0.05]無統(tǒng)計學(xué)差異。結(jié)論 茵梔黃口服制劑聯(lián)用雙歧桿菌活菌制劑可以提高新生兒黃疸的療效，同時可以有效減少新生兒黃疸的持續(xù)時間，加快黃疸的消退。

Objective To systematically review the efficacy and safety of Yinzhihuang Oral Preparation combined with Bifidobacteria Preparation in the treatment of neonatal jaundice. Methods RevMan 5.3 software was used to perform a Metaanalysis of randomized controlled trials (RCT) on the Yinzhihuang Oral Preparation combined with Bifidobacteria Preparation in the treatment of neonatal jaundice published from Jan. 2000 to Dec. 2018 in PubMed, Embase, CNKI, CBM,VIP and Wanfang database. Results A total of 14 RCTs were selected, with 1 042 cases in the intervention group and 972 cases in the control group. Metaanalysis showed that the cure rate of the intervention group was greater than that of the control group[RR=0.68, 95%CI(0.62, 0.76), P<0.01], jaundice regression time was shorter than that of the control group[MD=1.97, 95%CI (1.77, 2.17), P<0.01] and daily average bilirubin decline was higher than that of the control group[MD=10.64, 95%CI (9.07, 12.20), P<0.01], and subgroup analysis results were consistent. In terms of safety, the rate of ADR in the intervention group was lower than that in the control group[RR=1.96, 95%CI (1.23, 3.13), P<0.01], but subgroup analysis showed that, the rate of ADR in the intervention group was lower than that in the blank control group[RR=2.51, 95%CI (1.12, 5.66), P=0.03]. There had no statistical difference in Yinzhihuang Oral Preparation group[RR=1.98, 95%CI (0.90, 4.33), P>0.05] and Bifidobacteria Preparation group[RR=1.45, 95%CI (0.62, 3.39), P>0.05]. Conclusion Yinzhihuang Oral Preparation combined with Bifidobacteria Preparation can improve the efficacy of neonatal jaundice, and can effectively reduce the duration of neonatal jaundice and accelerate the regression of jaundice.